By Sherri Oslick --
Teva Branded Pharmaceutical
Products R&D Inc. et al. v. Perrigo Pharmaceuticals Co. et al.
1:12-cv-01101; filed September 5, 2012 in the District Court of Delaware
• Plaintiffs: Teva Branded
Pharmaceutical Products R&D Inc.; Teva Respiratory LLC; Norton (Waterford) Ltd.; Norton Healthcare Ltd.
• Defendants: Perrigo Pharmaceuticals Co.; Perrigo Co.; Catalent Pharma Solutions LLC
Infringement of U.S. Patent Nos. 7,566,445 ("Medicinal Aerosols and Methods of Delivery Thereof," issued July 28, 2009) and 7,105,152 ("Suspension Aerosol Formulations," issued September 12, 2006) following a Paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Teva's ProAir® HFA Inhalation Aerosol (albuterol sulfate, used for the treatment or prevention of bronchospasm with reversible obstructive airway disease in patients 4 years of age and older and for the prevention of exercise-induced bronchospasm in patients 4 years of age and older). View the complaint here.
Medicis Pharmaceutical Corp. v. Actavis Mid Atlantic LLC
1:12-cv-01091; filed August 31, 2012 in the District Court of Delaware
Infringement of U.S. Patent No. 8,236,816 ("2x2x2 Week Dosing Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 3.75% Imiquimod," issued August 7, 2012) following a Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Medicis' Zyclara® Cream (3.75% imiquimod cream, used for the topical treatment of clinically typical, visible, or palpable actinic keratoses ("AK") of the full face or balding scalp in immunocompetent adults). View the complaint here.